Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Alkermes Bounces Back -- but Not Enough

TheMotleyFool

0 0

Alkermes (NASDAQ: ALKS) turned in a solid-enough quarter, but a pullback in guidance for its growth-driver antipsychotic drug Aristada led investors to fret over the biotech's near-term future.

Metric

Q2 2019

Quelle Fool.com

Like: 0

ALKS

Share